ClinicalTrials.Veeva

Menu

Ventricular Arrhythmias After Pulmonary Vein Isolation

U

Universitätsklinikum Hamburg-Eppendorf

Status

Completed

Conditions

Atrial Fibrillation
Ventricular Arrhythmias

Study type

Observational

Funder types

Other

Identifiers

NCT02699255
WF-01/16

Details and patient eligibility

About

The investigators study aimed to observe the occurrence of new premature ventricular complexes and other ventricular arrhythmias after pulmonary vein isolation.

Full description

Atrial fibrillation is the most common arrhythmia with a lifetime risk for development of over 20%. Pulmonary vein isolation is now established as therapy of choice for patients with symptomatic atrial fibrillation. It is well known that this interventional therapy inevitably modulates the intracardiac autonomic nervous system. While this ablation might alter atrial electrophysiology beneficially, the impact on ventricular electrophysiology remains unclear.

Enrollment

111 patients

Sex

All

Ages

18 to 80 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Age > 18 years
  • Paroxysmal atrial fibrillation scheduled to undergo pulmonary vein isolation

Exclusion criteria

  • Age < 18 years
  • Persistent atrial fibrillation
  • Life expectancy less than 12 months
  • Acute myocardial infarction, coronary artery bypass graft surgery, open heart surgery, or percutaneous transluminal coronary angioplasty within less than 3 months prior to inclusion
  • Documentation of >30 premature ventricular complexes per hour, salvos or ventricular tachycardias prior to atrial fibrillation ablation

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems